Opioid manufacturer Amneal settles for role in drug crisis

The settlement, worth more than $270 million, follows claims that Amneal – which manufactured nearly 9 billion generic opioid pills between 2006 and 2019 – “knowingly failed to monitor and report suspicious orders from its customers,” causing it to overuse prescription of opioids is possible. the Delaware Department of Justice.

It comes amid a surge in overdoses in Kent and Sussex counties, with state police issuing multiple safety advisories after 125 suspected overdoses were reported in the state in one week. Analysis by the Delaware National Guard found that many of the drugs involved in the overdoses included both xylazine, the veterinary tranquilizer also known as “tranq,” and the synthetic opioid fentanyl.

Amneal has agreed to provide $92.5 million in cash over the next 10 years to the states involved in the settlement, the Delaware Department of Justice said. As with previous settlements, Delaware’s payout will go to the state’s Prescription Opioid Settlement Distribution Fund, which will then distribute the money to organizations working to tackle addiction.